{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:33:15Z","timestamp":1793298795501,"version":"4.5.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","funder":[{"name":"Magee-Womens Research Institute","award":["Research and Education Grant; MWRI-Penn State Behrend SEED Grant"],"award-info":[{"award-number":["Research and Education Grant; MWRI-Penn State Behrend SEED Grant"]}],"id":[{"id":"https:\/\/ror.org\/00rnw4e09","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To determine whether periurethral estrogen application is noninferior to intravaginal estrogen application for the prevention of urinary tract infections (UTIs) in postmenopausal individuals with laboratory-proven recurrent UTI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>The TAPER (Techniques of Applying Vaginal Estrogen for Prevention of Recurrent Urinary Tract Infections) trial was a single-center, nonblinded, randomized noninferiority trial that compared outcomes after a twice-weekly intravaginal estradiol applicator instillation of 1.0 g cream (intravaginal) compared with periurethral digital application of 0.5 g cream (periurethral) in postmenopausal individuals with recurrent UTIs. The primary outcome was the proportion of UTI-free participants at 6 months postintervention. Secondary outcomes included number of UTIs, the amount of time elapsed to the first UTI, vaginal pH, PGI-I (Patient Global Impression of Improvement) scores, patient experience with the study drug, study drug adverse effects, and urinary and sexual function. To achieve 80% power with a type 1 error of 5% and to account for loss to follow-up, 114 participants needed to be randomized based on a noninferiority margin of 25%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      Of 270 eligible individuals, 114 consented and were randomized (57 intravaginal, 57 periurethral). Participants were predominantly White (92.1%) with a mean age of 71.1 years (range 52\u201393). Participants reported a median of three UTIs in the 12 months before enrollment. Individuals randomized to periurethral estrogen application had a similar proportion of UTI-free participants at 6 months as those randomized to intravaginal estrogen application (50.9% vs 52.6%; risk difference, \u22121.75 percentage points; 95% CI, \u221220.0 to 17.0 percentage points). Both groups experienced a decrease in vaginal pH at 6 months; the decreases did not differ by application method (\u22121.2 intravaginal vs \u22120.8 periurethral,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =.30). Participants assigned to intravaginal estrogen were more likely to experience vaginal itching after 3 months of use than those assigned to periurethral application (24.0% vs 2.4%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;.01). Other outcomes did not differ by route of estrogen application.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>For postmenopausal individuals who are experiencing recurrent UTI, periurethral application of estradiol cream is noninferior to intravaginal application for UTI prevention. Both application methods resulted in approximately half of the participants being UTI-free at 6 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CLINICAL TRIAL REGISTRATION:<\/jats:title>\n                    <jats:p>ClinicalTrials.gov, NCT05472779.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/aog.0000000000006376","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T01:00:09Z","timestamp":1784854809000},"page":"671-679","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Vaginal Estrogen Application Techniques for Prevention of Urinary Tract Infection"],"prefix":"10.1097","volume":"148","author":[{"given":"Stephanie W.","family":"Zuo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin E.","family":"Mowers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shea","family":"Hem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halina M.","family":"Zyczynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon L.","family":"Hillier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary F.","family":"Ackenbom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"R1-20261015","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1080\/13697137.2018.1551871","article-title":"The etiology and management of recurrent urinary tract infections in postmenopausal women","volume":"22","author":"Jung","year":"2019","journal-title":"Climacteric"},{"key":"R2-20261015","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ogc.2021.05.005","article-title":"Recurrent urinary tract infections: diagnosis, treatment, and prevention","volume":"48","author":"Peck","year":"2021","journal-title":"Obstet Gynecol Clin North Am"},{"key":"R3-20261015","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1111\/jocn.12422","article-title":"Older women's experiences of suffering from urinary tract infections","volume":"23","author":"Eriksson","year":"2014","journal-title":"J Clin Nurs"},{"key":"R4-20261015","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/SPV.0000000000001065","article-title":"Baseline characteristics, evaluation, and management of women with complaints of recurrent urinary tract infections","volume":"27","author":"Dieter","year":"2021","journal-title":"Female Pelvic Med Reconstr Surg"},{"key":"R5-20261015","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/s41585-018-0106-x","article-title":"Nonantibiotic prevention and management of recurrent urinary tract infection","volume":"15","author":"Sihra","year":"2018","journal-title":"Nat Rev Urol"},{"key":"R6-20261015","doi-asserted-by":"crossref","first-page":"e80074","DOI":"10.1371\/journal.pone.0080074","article-title":"Vaginal pH and microbicidal lactic acid when lactobacilli dominate the microbiota","volume":"8","author":"O'Hanlon","year":"2013","journal-title":"PLoS One"},{"key":"R7-20261015","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/SPV.0000000000001051","article-title":"Impact of vaginal estrogen on the urobiome in postmenopausal women with recurrent urinary tract infection","volume":"28","author":"Jung","year":"2022","journal-title":"Female Pelvic Med Reconstr Surg"},{"key":"R8-20261015","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1089\/jwh.2007.0407","article-title":"A retrospective managed care claims data analysis of medication adherence to vaginal estrogen therapy: implications for clinical practice","volume":"17","author":"Shulman","year":"2008","journal-title":"J Womens Health (Larchmt)"},{"key":"R9-20261015","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.maturitas.2012.12.004","article-title":"Women's preferences toward attributes of local estrogen therapy for the treatment of vaginal atrophy","volume":"74","author":"Mattsson","year":"2013","journal-title":"Maturitas"},{"key":"R10-20261015","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2147\/IJWH.S41897","article-title":"Improved compliance and patient satisfaction with estradiol vaginal tablets in postmenopausal women previously treated with another local estrogen therapy","volume":"5","author":"Minkin","year":"2013","journal-title":"Int J Womens Health"},{"key":"R11-20261015","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.urology.2020.05.058","article-title":"Effective prevention of recurrent utis with vaginal estrogen: pearls for a urological approach to genitourinary syndrome of menopause","volume":"151","author":"Buck","year":"2021","journal-title":"Urology"},{"key":"R12-20261015","doi-asserted-by":"crossref","first-page":"107893","DOI":"10.1016\/j.cct.2025.107893","article-title":"Periurethral versus intravaginal application of vaginal estrogen for the prevention of urinary tract infections in postmenopausal women: design of a randomized non-inferiority trial","volume":"153","author":"Zuo","year":"2025","journal-title":"Contemp Clin Trials"},{"key":"R13-20261015","first-page":"20","article-title":"Teach-Back: a simple technique to enhance patients' understanding","volume":"25","author":"Bodenheimer","year":"2018","journal-title":"Fam Pract Manag"},{"key":"R14-20261015","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1471-0528.1996.tb09741.x","article-title":"A comparative study of safety and efficacy of continuous low dose oestradiol released from a vaginal ring compared with conjugated equine oestrogen vaginal cream in the treatment of postmenopausal urogenital atrophy","volume":"103","author":"Ayton","year":"1996","journal-title":"Br J Obstet Gynaecol"},{"issue":"2","key":"R15-20261015","first-page":"CD005131","article-title":"Oestrogens for preventing recurrent urinary tract infection in postmenopausal women","author":"Perrotta","year":"2008","journal-title":"The Cochrane Database of Systematic Reviews"},{"key":"R16-20261015","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/nau.20189","article-title":"Normative values for the American Urological Association Symptom Index (AUA-7) and short form Urogenital Distress Inventory (UDI-6) in patients 65 and older presenting for non-urological care","volume":"24","author":"Svatek","year":"2005","journal-title":"Neurourol Urodyn"},{"key":"R17-20261015","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/j.1743-6109.2009.01635.x","article-title":"Development and validation of a 6-item version of the Female Sexual Function Index (FSFI) as a diagnostic tool for female sexual dysfunction","volume":"7","author":"Isidori","year":"2010","journal-title":"J Sex Med"},{"key":"R18-20261015","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/S0002-9378(99)70597-1","article-title":"A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women","volume":"180","author":"Eriksen","year":"1999","journal-title":"Am J Obstet Gynecol"},{"key":"R19-20261015","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJM199309093291102","article-title":"A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections","volume":"329","author":"Raz","year":"1993","journal-title":"N Engl J Med"},{"key":"R20-20261015","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/SPV.0000000000000749","article-title":"Vaginal estrogen for the prevention of recurrent urinary tract infection in postmenopausal women: a randomized clinical trial","volume":"27","author":"Ferrante","year":"2021","journal-title":"Female Pelvic Med Reconstr Surg"},{"key":"R22-20261015","doi-asserted-by":"crossref","first-page":"6","DOI":"10.4103\/ijp.IJP_545_18","article-title":"A comparative study of alpha-1a blockers (tamsulosin) versus estrogens in the treatment of lower urinary tract symptoms in perimenopausal females","volume":"52","author":"Maiti","year":"2020","journal-title":"Indian J Pharmacol"},{"key":"R23-20261015","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.maturitas.2015.05.010","article-title":"Low-dose 17-\u03b2-estradiol cream for vaginal atrophy in a cohort without prolapse: serum levels and vaginal response including tissue biomarkers associated with tissue remodeling","volume":"81","author":"Illston","year":"2015","journal-title":"Maturitas"},{"key":"R24-20261015","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejogrb.2010.07.006","article-title":"The effect of hormonal status on the expression of estrogen and progesterone receptor in vaginal wall and periurethral tissue in urogynecological patients","volume":"153","author":"Skala","year":"2010","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R25-20261015","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.maturitas.2008.07.015","article-title":"Estrogen therapy influence on periurethral vessels in postmenopausal incontinent women using Dopplervelocimetry analysis","volume":"61","author":"Kobata","year":"2008","journal-title":"Maturitas"},{"key":"R26-20261015","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1067\/mob.2003.341","article-title":"Placement of the vaginal 17beta-estradiol tablets in the inner or outer one third of the vagina affects the preferential delivery of 17beta-estradiol toward the uterus or periurethral areas, thereby modifying efficacy and endometrial safety","volume":"189","author":"Cicinelli","year":"2003","journal-title":"Am J Obstet Gynecol"},{"key":"R27-20261015","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2147\/IJWH.S57900","article-title":"Postmenopausal vaginal atrophy: evaluation of treatment with local estrogen therapy","volume":"6","author":"Minkin","year":"2014","journal-title":"Int J Womens Health"},{"key":"R28-20261015","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1097\/GME.0000000000001609","article-title":"The 2020 genitourinary syndrome of menopause position statement of the North American Menopause Society","volume":"27","year":"2020","journal-title":"Menopause"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000006376","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:01:40Z","timestamp":1792069300000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000006376"}},"subtitle":["A Randomized Trial"],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000006376","relation":{},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"assertion":[{"value":"2026-04-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}